New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDihexa vs Prostamax

Dihexa vs Prostamax

Side-by-side comparison of key properties, dosing, and research.

Cognitive Enhancement
Dihexa
Anti-Aging & Longevity
Prostamax
Summary
Dihexa is a potent experimental oligopeptide derived from angiotensin IV that dramatically enhances synaptogenesis. Preclinical research shows cognitive enhancement orders of magnitude more potent than BDNF — it is considered one of the most powerful nootropic compounds in research, but has very limited human safety data.
Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
Half-Life
Unknown (limited pharmacokinetic data)
Short (minutes); sustained gene-regulatory effects
Admin Route
Oral, SubQ, Topical
SubQ, Oral
Research
Typical Dose
5–10 mg
10 mg per day
Frequency
Daily
Daily for 10–30 days
Key Benefits
  • Dramatically increases synapse formation (potentially 10 million× more potent than BDNF in animal models)
  • Enhances memory and learning
  • May reverse cognitive decline
  • Improves neuroplasticity and executive function
  • Long-lasting cognitive benefits from short courses
  • Potential therapeutic agent for Alzheimer's
  • Supports normalization of prostate tissue architecture
  • May reduce prostate enlargement associated with BPH
  • Anti-inflammatory effects on prostatic tissue
  • Reduces prostate cell apoptosis from oxidative stress
  • Potential support in chronic prostatitis
  • Anti-aging effects on prostate glandular tissue
  • Complementary to conventional BPH therapies
Side Effects
  • Headache
  • Irritability
  • Brain fog during washout period
  • Unknown long-term effects (insufficient data)
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse urological events reported at standard doses
Stacks With